Close Menu

Lucence Diagnostics LiquidHallMark

Oct 24, 2018

Lucence Diagnostics launched the LiquidHallMark blood test for detecting multiple cancer-related mutations and viral targets for clinical use in Asia. Physicians can use the test to select targeted therapies and to monitor treatment response. The liquid biopsy panel identifies clinically relevant genomic alterations including somatic mutations, microsatellite instability, and viral DNA from ctDNA in blood. It was developed for cancers that are particularly prevalent in Asia, such as breast, colon, lung, and nasopharyngeal cancers. The test is based on Lucence's proprietary technology called AmpliMark that has sensitivity and specificity of up to 99.9 percent, the company said. 

More Like This

Oct 14, 2019

Predictive Laboratories FertilityDX

Predictive Laboratories launched FertilityDX, a genetic testing service that allows physicians to tailor fertility treatments. The test provides information in three areas, the firm said — causes of infertility, risks of pregnancy complications, and risks for serious genetic conditions in the offspring. As part of the service patients are provided pretest counseling, and physicians received an easy-to-understand final report, as well as access to genetic consultants. 

Oct 14, 2019

PerkinElmer PG-Seq Rapid Non-Invasive Preimplantation Genetic Testing Kit

PerkinElmer launched the PG-Seq Rapid Non-Invasive Preimplantation Genetic Testing for Anueploidy kit, which tests spent embryo culture media for chromosomal abnormalities during in vitro treatment. Preimplantation genetic testing for aneuploidiy is used to identify viable embryos and has typically involved a biopsy by creating an opening in the outer coating prior to removal and testing a few cells. Recent studies have demonstrated, however, that an embryo releases small amounts of DNA into the culture media in which it is growing, allowing for the surrounding fluid to be genetically tested. PerkinElmer's kit tests the spent embryo culture to detect aneuploidies and structural rearrangements, including unbalanced translocations and segmental errors.

 

Oct 11, 2019

Sema4 Expanded Carrier Screening

Sema4 has launched a larger Expanded Carrier Screen for family planning with personalized residual risk.

The test analyzes 502 genes associated with clinically relevant conditions, up from 283 genes, to cover more rare diseases. The test detects more high-risk pregnancies and identifies up to 30 times more carrier couples, Sema4 CEO Eric Schadt said in a statement. It also incorporates low-pass genome analysis to detect ancestry markers that to refine the accuracy of results.

Oct 11, 2019

Dante Labs Whole Genome, Whole GenomeZ Sequencing Service

Dante Labs has launched its Whole Genome and WholeGenomeZ sequencing test services. The firm said that the service — located at its Illumina-backed, Italy-based automated sequencing center — offers reports and raw data for users with a two-week turnaround time. According to Dante Labs, the Premium Whole Genome costs €899 (or $949) for the fastest turnaround time versus €599 (or $649) for the standard turnaround time. The price for the Super Premium Whole GenomeZ is €1,399 (or $1,499) for the fast turnaround time, and €899 (or $999) for the standard turnaround time. 

Oct 10, 2019

Predictive Laboratories ARTguide Test

Salt Lake City, Utah-based Predictive Laboratories has commercially launched its ARTguide DNA-based blood test, which examines the risk for endometriosis and other genetic causes of infertility in women. According to the firm, the test identifies hundreds of genetic markers of endometriosis and 80 other additional mutations causing conditions that may impact fertility.  

Oct 10, 2019

Co-Diagnostics Vector Smart ZDC Test

Co-Diagnostics has commercially launched its Vector Smart ZDC test, which is used to identify the presence of Zika, dengue, and chikungunya in mosquito populations. The firm said that its line of Vector Smart PCR products are validated using extractions from mosquito samples to reduce the possibility of a false negative result due to improper extraction. 

Oct 01, 2019

NanoString nCounter Human Organ Transplant Panel

NanoString Technologies has launched its nCounter Human Organ Transplant panel, a new gene expression panel for evaluating the immune response following organ transplantation. The firm said that it created the assay in collaboration with the Banff Foundation for Allograft Pathology. The panel covers 770 genes and is customizable. It is designed for use with the predominant transplant organs including kidney, heart, lung, and liver. Genes included on the panel are involved in 37 pathways that are components of the immune response, tissue injury, and mechanisms of action for immunosuppressive drugs. The panel also includes probes to detect common viral infections that can cause issues with transplants, including BK polyomavirus, cytomegalovirus, and Epstein-Barr virus.

Oct 01, 2019

Ambry Genetics +RNAinsight

Ambry Genetics has launched +RNAinsight, a combined DNA and RNA genetic test for hereditary cancer syndromes that is designed to return more certain results to patients by using RNA sequencing to definitively classify otherwise ambiguous genetic alterations. While the RNA aspect of the test does not include all known cancer risk genes, it does focus on a subset that includes BRCA1 and 2, TP53, PTEN, and PALB2, among others. Ambry said that the turnaround time for the combined test matches the company's DNA-only hereditary cancer panel.

Oct 01, 2019

ATCC Genome Portal

ATCC has launched its ATCC Genome Portal, a publicly available database of reference-quality genome sequences that are matched to authenticated ATCC biological materials. Integrating low-passaged materials, standardized next-generation sequencing, and a hybrid assembly approach, the tool produces complete reference-quality genomes by combining highly accurate short reads with ultra-long reads. ATCC said that it has launched the portal with an initial 250 genome sequences of widely used bacterial strains.

Sep 30, 2019

T2 Biosystems T2Resistance Panel

The T2 Biosystems T2Resistance Panel for genotypic antibiotic resistance marker testing is now available as a research use only test in the US. The panel uses the firm's T2Dx instrument and identifies 13 genes conferring resistance to common empiric antibiotic therapies, such as carbapenems, vancomycin, and penicillin, directly from whole blood within three to five hours. The panel received breakthrough device designation from the US Food and Drug Administration earlier this year and is on track to receive CE mark by the end of 2019.

Sep 27, 2019

nRichDx: Revolution System

nRichDx has launched its high-yield sample prep Revolution System. The Irvine, California firm designed the in vitro diagnostic system to increase liquid biopsy-based test sensitivity by delivering more target input for molecular assays. Researchers can currently use the platform to extract cell-free DNA from plasma and urine, followed by eventual applications for circulating tumor cells, exosomes, and total cell-free nucleic acid in the development pipeline. 

Sep 27, 2019

Sysmex Inostics SafeSeq Breast Cancer and Head and Neck Panels, SafeSeq Rapid Custom Development Program

Sysmex Inostics has launched its SafeSeq Breast Cancer and Head and Neck Cancer Panels, which both run on the firm's next-generation sequencing SafeSeq platform. The SafeSeq Breast Cancer Panel tests for mutations affecting the PIK3CA, ESR1, TP53, ERBB2, AKT1, and KRAS genes in ER-positive HER2-negative breast cancer samples, the firm noted. The SafeSEQ Breast cancer panel offers sensitive detection of mutant ctDNA, which Sysmex believes is well suited for disease monitoring to assess treatment response, minimal residual disease, and molecular relapse. Sysmex's SafeSeq Head and Neck Cancer panel tests for mutations in the genes PIK3CA, CDKN2A, HRAS, and TP53. 

In addition to the cancer panels, Sysmex now offers its SafeSeq Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. The firm said that users can assemble targeted genes and mutations into highly sensitive fit-for-purpose assays with customer-selected levels of analytical and clinical validation.

Sep 26, 2019

Almac Diagnostics Services ClaraT Total mRNA Report

Almac Diagnostic Services of Craigavon, Northern Ireland, is launching the complete version of its ClaraT Total mRNA Report at the European Society for Medical Oncology meeting in Barcelona this weekend. The report content has expanded from an initial version launched a year ago, Almac said, and now includes 92 gene expression signatures, 100 single-gene drug targets, and more than 7,000 additional biology-linked genes categorized by 10 hallmarks of cancer. The research-use-only product uses RNA sequencing alongside proprietary bioinformatics to provide investigators with an interactive report that facilitates visualization of novel molecular subgroups within a sample cohort and key discriminating biology in individual tumor samples, the company said.

Sep 25, 2019

Fluidigm Cadmium Metal Labeling Kits for Mass Cytometry

Fluidigm has releases seven new Maxpar cadmium metal labeling kits for use with mass cytometry: 106Cd, 110Cd, 111Cd, 112Cd, 113Cd, and 116Cd. Fluidigm said that the kits will enable researchers to easily expand mass cytometry panels as demand grows for larger panels to interrogate the immunome, cancer, and other complex diseases. When the labels are used with existing panels comprising more than 20 parameters, researchers can simultaneously profile more than 50 cell surface and intracellular parameters in a single run. Researchers can also use the kits to customize Fluidigm pre-designed panels, including the Maxpar Direct Immune Profiling Assay, Fluidigm said.

Sep 25, 2019

Roche Cobas EBV, BKV Tests

Roche has launched the Cobas EBV and BKV tests for Epstein-Barr virus and BK virus in countries accepting the CE mark. The tests are for use with Roche's Cobas 6800/8800 Systems. The real-time PCR tests leverages dual target technology help clinicians manage the risk of infection for severely immunocompromised transplant patients and assess if these patients are at risk of of developing disease, which can contribute to organ rejection, the company said. 

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Sponsored by
Sunquest

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.